NCT01447446

Brief Summary

This prospective, multicenter, observational cohort study will evaluate the efficacy and safety of pegylated interferon alfa (peginterferon alfa) (e.g. Pegasys) plus ribavirin and treatment regimens containing direct-acting antivirals in participants with chronic hepatitis C who are treatment-naïve or treatment-experienced and HIV HCV co-infected. Data will be collected from participants receiving treatment according to current Summary of Product Characteristics (SPC) and local labeling for the duration of their treatment and a 24-week follow-up.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
4,442

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2011

Longer than P75 for all trials

Geographic Reach
26 countries

268 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 4, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 6, 2011

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
1.7 years until next milestone

Results Posted

Study results publicly available

March 30, 2017

Completed
Last Updated

March 30, 2017

Status Verified

December 1, 2016

Enrollment Period

3.8 years

First QC Date

October 4, 2011

Results QC Date

September 27, 2016

Last Update Submit

February 10, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Percentage of Participants With Sustained Virological Response at 24 Weeks Post Completion of the Treatment Period (SVR24)

    SVR24 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (\<) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to \[\<=\] 50 IU/mL) at 24 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be \<=50 IU/mL. SVR24 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection \<= 50 IU/mL at 24 weeks post completion of the treatment period.

    24 weeks after end of treatment (up to 118 weeks)

  • Percentage of Participants With Sustained Virological Response at 12 Weeks Post Completion of the Treatment Period (SVR12)

    SVR12 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (\<) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to \[\<=\] 50 IU/mL) at 12 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be \<=50 IU/mL. SVR12 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection \<= 50 IU/mL at 12 weeks post completion of the treatment period.

    12 weeks after end of treatment (up to 118 weeks)

Secondary Outcomes (12)

  • Virological Response at Various on Treatment Time Points and End of Treatment (EOT)

    Week 4, 12 and End of treatment (EOT) (up to 96 weeks)

  • Virological Relapse After End of Treatment

    Up to 24 weeks after EOT (up to 118 weeks)

  • Virological Breakthrough

    Up to EOT (up to 118 weeks)

  • Percentage of Participants With Sustained Virological Response (SVR) in Participants With Dose Reductions or Treatment Interruptions

    Up to first 12 weeks of treatment

  • Percentage of Participants With Very Rapid Virological Response, Rapid Virological Response, Complete Early Virological Response and Partial Early Virological Response (pEVR) During First 12 Weeks

    Up to 12 weeks

  • +7 more secondary outcomes

Study Arms (6)

Dual Therapy: Peg-IFN Alfa-2a + Ribavirin

Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a \[peg-IFN Alfa-2a\] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.

Drug: Peg-IFN Alfa-2aDrug: Ribavirin

Dual Therapy: Peg-IFN Alfa-2b + Ribavirin

Participants with CHC receiving dual therapy (pegylated interferon alfa-2b \[peg-IFN Alfa-2b\] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.

Drug: Peg-IFN Alfa-2bDrug: Ribavirin

Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin

Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.

Drug: Peg-IFN Alfa-2aDrug: RibavirinDrug: Boceprevir

Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin

Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.

Drug: Peg-IFN Alfa-2bDrug: RibavirinDrug: Boceprevir

Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin

Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.

Drug: Peg-IFN Alfa-2aDrug: RibavirinDrug: Telaprevir

Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin

Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.

Drug: Peg-IFN Alfa-2bDrug: RibavirinDrug: Telaprevir

Interventions

Peg-IFN Alfa-2a according to standard of care and in line with local labeling.

Dual Therapy: Peg-IFN Alfa-2a + RibavirinTriple Therapy: Boceprevir + Peg-IFN Alfa-2a + RibavirinTriple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin

Peg-IFN Alfa-2b according to standard of care and in line with local labeling.

Dual Therapy: Peg-IFN Alfa-2b + RibavirinTriple Therapy: Boceprevir + Peg-IFN Alfa-2b + RibavirinTriple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin

Ribavirin according to standard of care and in line with local labeling.

Dual Therapy: Peg-IFN Alfa-2a + RibavirinDual Therapy: Peg-IFN Alfa-2b + RibavirinTriple Therapy: Boceprevir + Peg-IFN Alfa-2a + RibavirinTriple Therapy: Boceprevir + Peg-IFN Alfa-2b + RibavirinTriple Therapy: Telaprevir + Peg-IFN Alfa-2a + RibavirinTriple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin

Boceprevir according to standard of care and in line with local labeling.

Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + RibavirinTriple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin

Telaprevir according to standard of care and in line with local labeling.

Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + RibavirinTriple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Chronic hepatitis C (CHC) participants (naïve or treatment experienced, including HIV HCV co-infected) receiving combination therapy with pegylated interferons plus ribavirin or treatment regimens containing direct-acting antivirals.

You may qualify if:

  • Adult (according to local legislation) participants
  • Chronic hepatitis C (HCV)
  • Naive or treatment experienced, HIV-HCV co-infected or HCV mono-infected
  • Receiving treatment for HCV with pegylated interferons plus ribavirin or regimens containing direct-acting antivirals (DAA) according to standard of care and in line with current SPC/local labeling

You may not qualify if:

  • Contraindications according to SPC/local labeling
  • Treatment started \>4 weeks before entering study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (271)

Unknown Facility

Antwerp, 2018, Belgium

Location

Unknown Facility

Antwerp, 2060, Belgium

Location

Unknown Facility

Bouge, 5004, Belgium

Location

Unknown Facility

Brussels, 1000, Belgium

Location

Unknown Facility

Brussels, 1020, Belgium

Location

Unknown Facility

Brussels, 1070, Belgium

Location

Unknown Facility

Brussels, 1180, Belgium

Location

Unknown Facility

Brussels, 1190, Belgium

Location

Unknown Facility

Brussels, 1200, Belgium

Location

Unknown Facility

Edegem, 2650, Belgium

Location

Unknown Facility

Ghent, 9000, Belgium

Location

Unknown Facility

Gilly (Charleroi), 6000, Belgium

Location

Unknown Facility

Hasselt, 3500, Belgium

Location

Unknown Facility

Heusy, 4802, Belgium

Location

Unknown Facility

Kortrijk, 8500, Belgium

Location

Unknown Facility

Leuven, 3000, Belgium

Location

Unknown Facility

Liège, 4000, Belgium

Location

Unknown Facility

Mons, 7000, Belgium

Location

Unknown Facility

Montignies-sur-Sambre, 6061, Belgium

Location

Unknown Facility

Namur, 5000, Belgium

Location

Unknown Facility

Ostend, 8400, Belgium

Location

Unknown Facility

Roeselare, 8800, Belgium

Location

Unknown Facility

Verviers, 4800, Belgium

Location

Unknown Facility

Alexandria, 0, Egypt

Location

Unknown Facility

Alexandria, Egypt

Location

Unknown Facility

Cairo, 0, Egypt

Location

Unknown Facility

Cairo, Egypt

Location

Unknown Facility

Giza, Egypt

Location

Unknown Facility

Tanta, Egypt

Location

Unknown Facility

Kohtla-Järve, 31025, Estonia

Location

Unknown Facility

Pärnu, 80010, Estonia

Location

Unknown Facility

Tallinn, 10138, Estonia

Location

Unknown Facility

Tallinn, 10617, Estonia

Location

Unknown Facility

Tartu, 51014, Estonia

Location

Unknown Facility

Aix-en-Provence, 13616, France

Location

Unknown Facility

Amiens, 80054, France

Location

Unknown Facility

Argenteuil, 95107, France

Location

Unknown Facility

Avignon, 84902, France

Location

Unknown Facility

Besançon, 25000, France

Location

Unknown Facility

Besançon, 25030, France

Location

Unknown Facility

Béziers, 34500, France

Location

Unknown Facility

Boulogne-Billancourt, 92104, France

Location

Unknown Facility

Bourgoin, 38300, France

Location

Unknown Facility

Caen, 14033, France

Location

Unknown Facility

Chambray-lès-Tours, 37171, France

Location

Unknown Facility

Clichy, 92118, France

Location

Unknown Facility

Creil, 60109, France

Location

Unknown Facility

Créteil, 94010, France

Location

Unknown Facility

Épinay-sur-Seine, 93806, France

Location

Unknown Facility

Évry, 91014, France

Location

Unknown Facility

Freyming-Merlebach, 57804, France

Location

Unknown Facility

Gonesse, 95503, France

Location

Unknown Facility

Grasse, 06130, France

Location

Unknown Facility

Hyères, 83407, France

Location

Unknown Facility

La Tronche, 38700, France

Location

Unknown Facility

Lagny-sur-Marne, 77405, France

Location

Unknown Facility

Lille, 59037, France

Location

Unknown Facility

Limoges, 87042, France

Location

Unknown Facility

Lomme, 59462, France

Location

Unknown Facility

Lyon, 69009, France

Location

Unknown Facility

Mantes-la-Jolie, 78200, France

Location

Unknown Facility

Marseille, 13285, France

Location

Unknown Facility

Meaux, 77104, France

Location

Unknown Facility

Montpellier, 34070, France

Location

Unknown Facility

Montpellier, 34295, France

Location

Unknown Facility

Nice, 06202, France

Location

Unknown Facility

Nîmes, 30029, France

Location

Unknown Facility

Orange, 84100, France

Location

Unknown Facility

Orléans, 45100, France

Location

Unknown Facility

Paris, 75571, France

Location

Unknown Facility

Paris, 75651, France

Location

Unknown Facility

Paris, 75679, France

Location

Unknown Facility

Paris, 75908, France

Location

Unknown Facility

Paris, 75970, France

Location

Unknown Facility

Pau, 64046, France

Location

Unknown Facility

Perpignan, 66046, France

Location

Unknown Facility

Pessac, 33604, France

Location

Unknown Facility

Reims, 51092, France

Location

Unknown Facility

Rennes, 35033, France

Location

Unknown Facility

Rouen, 76031, France

Location

Unknown Facility

Saint-Laurent-du-Var, 06700, France

Location

Unknown Facility

Saint-Nazaire, 44606, France

Location

Unknown Facility

Saint-Priest-en-Jarez, 42277, France

Location

Unknown Facility

Strasbourg, 67091, France

Location

Unknown Facility

Suresnes, 92151, France

Location

Unknown Facility

Toulon, 83000, France

Location

Unknown Facility

Toulouse, 31059, France

Location

Unknown Facility

Tourcoing, 59208, France

Location

Unknown Facility

Vandœuvre-lès-Nancy, 54511, France

Location

Unknown Facility

Vannes, 56017, France

Location

Unknown Facility

Villejuif, 94804, France

Location

Unknown Facility

Villeneuve Maguelone, 34751, France

Location

Unknown Facility

Villeneuve-Saint-Georges, 94195, France

Location

Unknown Facility

Aachen, 52074, Germany

Location

Unknown Facility

Berlin, 10243, Germany

Location

Unknown Facility

Berlin, 10777, Germany

Location

Unknown Facility

Burghausen, 84489, Germany

Location

Unknown Facility

Cologne, 50937, Germany

Location

Unknown Facility

Düsseldorf, 40237, Germany

Location

Unknown Facility

Erlangen, 91054, Germany

Location

Unknown Facility

Essen, 45122, Germany

Location

Unknown Facility

Kassel, 34117, Germany

Location

Unknown Facility

Lübeck, 23562, Germany

Location

Unknown Facility

Magdeburg, 39120, Germany

Location

Unknown Facility

Mannheim, 68167, Germany

Location

Unknown Facility

Rostock, 18057, Germany

Location

Unknown Facility

Rottenburg, 72108, Germany

Location

Unknown Facility

Tübingen, 72076, Germany

Location

Unknown Facility

Alexandroupoli, 68100, Greece

Location

Unknown Facility

Athens, 115 27, Greece

Location

Unknown Facility

Athens, 11522, Greece

Location

Unknown Facility

Athens, 11527, Greece

Location

Unknown Facility

Ioannina, 455 00, Greece

Location

Unknown Facility

Larissa, 41 110, Greece

Location

Unknown Facility

Nea Kifissia, 14564, Greece

Location

Unknown Facility

Pátrai, 265 04, Greece

Location

Unknown Facility

Thessaloniki, 546 42, Greece

Location

Unknown Facility

Ajka, H-8400, Hungary

Location

Unknown Facility

Balassagyarmat, 2660, Hungary

Location

Unknown Facility

Békéscsaba, 5600, Hungary

Location

Unknown Facility

Budapest, 1067, Hungary

Location

Unknown Facility

Budapest, 1083, Hungary

Location

Unknown Facility

Budapest, 1088, Hungary

Location

Unknown Facility

Budapest, 1097, Hungary

Location

Unknown Facility

Budapest, 1126, Hungary

Location

Unknown Facility

Budapest, H-1125, Hungary

Location

Unknown Facility

Debrecen, 4032, Hungary

Location

Unknown Facility

Debrecen, H-4031, Hungary

Location

Unknown Facility

Gyula, 5700, Hungary

Location

Unknown Facility

Kaposvár, 7400, Hungary

Location

Unknown Facility

Kecskemét, 6000, Hungary

Location

Unknown Facility

Miskolc, H-3501, Hungary

Location

Unknown Facility

Nyíregyháza, 4400, Hungary

Location

Unknown Facility

Pécs, 7624, Hungary

Location

Unknown Facility

Sopron, 9400, Hungary

Location

Unknown Facility

Szeged, 6720, Hungary

Location

Unknown Facility

Székesfehérvár, 8000, Hungary

Location

Unknown Facility

Szolnok, 5000, Hungary

Location

Unknown Facility

Szombathely, 9700, Hungary

Location

Unknown Facility

Tatabánya, 2800, Hungary

Location

Unknown Facility

Zalaegerszeg, 8900, Hungary

Location

Unknown Facility

Zalaegerszeg, 8901, Hungary

Location

Unknown Facility

Dublin, 4, Ireland

Location

Unknown Facility

Dublin, 8, Ireland

Location

Unknown Facility

Dublin, 9, Ireland

Location

Unknown Facility

Chieti, Abruzzo, 66013, Italy

Location

Unknown Facility

Bari, Apulia, 70124, Italy

Location

Unknown Facility

Bisceglie, Apulia, 70052, Italy

Location

Unknown Facility

Castellana Grotte, Apulia, 70013, Italy

Location

Unknown Facility

San Giovanni Rotondo, Apulia, 71013, Italy

Location

Unknown Facility

Reggio Calabria, Calabria, 89100, Italy

Location

Unknown Facility

Avellino, Campania, 83100, Italy

Location

Unknown Facility

Gragnano, Campania, 80054, Italy

Location

Unknown Facility

Marcianise, Campania, 81025, Italy

Location

Unknown Facility

Napoli, Campania, 80131, Italy

Location

Unknown Facility

Napoli, Campania, 80136, Italy

Location

Unknown Facility

Napoli, Campania, 80138, Italy

Location

Unknown Facility

Nocera Inferiore, Campania, 84014, Italy

Location

Unknown Facility

Nola, Campania, 80035, Italy

Location

Unknown Facility

Bologna, Emilia-Romagna, 40138, Italy

Location

Unknown Facility

Modena, Emilia-Romagna, 41100, Italy

Location

Unknown Facility

Parma, Emilia-Romagna, 43126, Italy

Location

Unknown Facility

Piacenza, Emilia-Romagna, 29121, Italy

Location

Unknown Facility

Udine, Friuli Venezia Giulia, 33100, Italy

Location

Unknown Facility

Rome, Lazio, 00149, Italy

Location

Unknown Facility

Rome, Lazio, 00152, Italy

Location

Unknown Facility

Rome, Lazio, 00161, Italy

Location

Unknown Facility

Rome, Lazio, 00165, Italy

Location

Unknown Facility

Rome, Lazio, 00189, Italy

Location

Unknown Facility

Genoa, Liguria, 16132, Italy

Location

Unknown Facility

Savona, Liguria, 17100, Italy

Location

Unknown Facility

Busto Arsizio, Lombardy, 21052, Italy

Location

Unknown Facility

Milan, Lombardy, 20122, Italy

Location

Unknown Facility

Milan, Lombardy, 20123, Italy

Location

Unknown Facility

Milan, Lombardy, 20132, Italy

Location

Unknown Facility

Milan, Lombardy, 20142, Italy

Location

Unknown Facility

Milan, Lombardy, 20157, Italy

Location

Unknown Facility

Milan, Lombardy, 20162, Italy

Location

Unknown Facility

Biella, Piedmont, 13900, Italy

Location

Unknown Facility

Cuorgnè (TO), Piedmont, 10082, Italy

Location

Unknown Facility

Omegna (VB), Piedmont, 28887, Italy

Location

Unknown Facility

Cagliari, Sardinia, 09042, Italy

Location

Unknown Facility

Cagliari, Sardinia, 09100, Italy

Location

Unknown Facility

Sassari, Sardinia, 07100, Italy

Location

Unknown Facility

Catania, Sicily, 95100, Italy

Location

Unknown Facility

Catania, Sicily, 95126, Italy

Location

Unknown Facility

Messina, Sicily, 98124, Italy

Location

Unknown Facility

Palermo, Sicily, 90127, Italy

Location

Unknown Facility

Torrette Di Ancona, The Marches, 60020, Italy

Location

Unknown Facility

Arezzo, Tuscany, 52100, Italy

Location

Unknown Facility

Florence, Tuscany, 50134, Italy

Location

Unknown Facility

Livorno, Tuscany, 57124, Italy

Location

Unknown Facility

Padua, Veneto, 35128, Italy

Location

Unknown Facility

Safat, 13041, Kuwait

Location

Unknown Facility

Baabda, 50, Lebanon

Location

Unknown Facility

Beirut, 11-236, Lebanon

Location

Unknown Facility

Beirut, 99999, Lebanon

Location

Unknown Facility

Beirut, Lebanon

Location

Unknown Facility

Nabatieh, Lebanon

Location

Unknown Facility

Tripoli, 371 Tripoli, Lebanon

Location

Unknown Facility

Casablanca, 20000, Morocco

Location

Unknown Facility

Casablanca, 20100, Morocco

Location

Unknown Facility

Casablanca, Morocco

Location

Unknown Facility

Fes, Morocco

Location

Unknown Facility

Marrakesh, Morocco

Location

Unknown Facility

Rabat, 504, Morocco

Location

Unknown Facility

Rabat, 62000, Morocco

Location

Unknown Facility

Skopje, 1000, North Macedonia

Location

Unknown Facility

Muscat, P.O Box 35, Oman

Location

Unknown Facility

Faisalabad, Pakistan

Location

Unknown Facility

Gujranwala, Pakistan

Location

Unknown Facility

Karachi, Pakistan

Location

Unknown Facility

Lahore, 20021, Pakistan

Location

Unknown Facility

Lahore, Pakistan

Location

Unknown Facility

Rawalpindi, Pakistan

Location

Unknown Facility

Almada, 2805-267, Portugal

Location

Unknown Facility

Amadora, 2700-020, Portugal

Location

Unknown Facility

Aveiro, 3810-096, Portugal

Location

Unknown Facility

Beja, 7801-849, Portugal

Location

Unknown Facility

Coimbra, 3041-801, Portugal

Location

Unknown Facility

Faro, 8000-386, Portugal

Location

Unknown Facility

Lisbon, 1349-019, Portugal

Location

Unknown Facility

Lisbon, 1649-035, Portugal

Location

Unknown Facility

Porto, 4099-001, Portugal

Location

Unknown Facility

Doha, P.O.Box 3051, Qatar

Location

Unknown Facility

Bucharest, 021105, Romania

Location

Unknown Facility

Bucharest, 022328, Romania

Location

Unknown Facility

Cluj-Napoca, 400162, Romania

Location

Unknown Facility

Constanța, Romania

Location

Unknown Facility

Iași, 700554, Romania

Location

Unknown Facility

Iași, 700620, Romania

Location

Unknown Facility

Timișoara, 300167, Romania

Location

Unknown Facility

Holy Makkah, 21583-Makkah P.O.Box-53356, Saudi Arabia

Location

Unknown Facility

Riyadh, 11159, Saudi Arabia

Location

Unknown Facility

Riyadh, 11211, Saudi Arabia

Location

Unknown Facility

Belgrade, 11000, Serbia

Location

Unknown Facility

Novi Sad, 21000, Serbia

Location

Unknown Facility

Gävle, 80187, Sweden

Location

Unknown Facility

Karlstad, 65185, Sweden

Location

Unknown Facility

Uppsala, 75185, Sweden

Location

Unknown Facility

Lugano, 6900, Switzerland

Location

Unknown Facility

Sankt Gallen, 9007, Switzerland

Location

Unknown Facility

Aleppo, 6448, Syria

Location

Unknown Facility

Kaohsiung City, 00833, Taiwan

Location

Unknown Facility

Kaohsiung City, 807, Taiwan

Location

Unknown Facility

Taichung, 40447, Taiwan

Location

Unknown Facility

Taipei, 100, Taiwan

Location

Unknown Facility

Taipei, 112, Taiwan

Location

Unknown Facility

Taoyuan District, 333, Taiwan

Location

Unknown Facility

Adana, 01100, Turkey (Türkiye)

Location

Unknown Facility

Ankara, 06100, Turkey (Türkiye)

Location

Unknown Facility

Ankara, 06290, Turkey (Türkiye)

Location

Unknown Facility

Ankara, 06800, Turkey (Türkiye)

Location

Unknown Facility

Ankara, Turkey (Türkiye)

Location

Unknown Facility

Hatay, 31040, Turkey (Türkiye)

Location

Unknown Facility

Istanbul, 34390, Turkey (Türkiye)

Location

Unknown Facility

ISTANBULt, Turkey (Türkiye)

Location

Unknown Facility

Izmir, 35100, Turkey (Türkiye)

Location

Unknown Facility

Kayseri, 38039, Turkey (Türkiye)

Location

Unknown Facility

Mersin, 33169, Turkey (Türkiye)

Location

Unknown Facility

Tokat Province, 60250, Turkey (Türkiye)

Location

Unknown Facility

Trabzon, 61080, Turkey (Türkiye)

Location

Unknown Facility

Al Ain City, P.O.Box 1006, United Arab Emirates

Location

Unknown Facility

Dubai, 4545, United Arab Emirates

Location

Unknown Facility

Sharjah city, P.O.Box: 5735 - Sharjah, UAE, United Arab Emirates

Location

Unknown Facility

Dundee, DD1 9SY, United Kingdom

Location

Unknown Facility

Hull, HU3 2JZ, United Kingdom

Location

Unknown Facility

London, E1 1BB, United Kingdom

Location

Unknown Facility

London, W2 1NY, United Kingdom

Location

Unknown Facility

Manchester, M8 5RB, United Kingdom

Location

Unknown Facility

Nottingham, NG7 2UH, United Kingdom

Location

MeSH Terms

Conditions

Hepatitis C, Chronic

Interventions

peginterferon alfa-2apeginterferon alfa-2bRibavirinN-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamidetelaprevir

Condition Hierarchy (Ancestors)

Hepatitis CBlood-Borne InfectionsCommunicable DiseasesInfectionsHepatitis, Viral, HumanVirus DiseasesFlaviviridae InfectionsRNA Virus InfectionsHepatitis, ChronicHepatitisLiver DiseasesDigestive System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

RibonucleosidesNucleosidesNucleic Acids, Nucleotides, and Nucleosides

Results Point of Contact

Title
Medical Communications
Organization
Hoffmann-La Roche

Study Officials

  • Clinical Trials

    Hoffmann-La Roche

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 4, 2011

First Posted

October 6, 2011

Study Start

September 1, 2011

Primary Completion

July 1, 2015

Study Completion

July 1, 2015

Last Updated

March 30, 2017

Results First Posted

March 30, 2017

Record last verified: 2016-12

Locations